Mediterr J Rheumatol 2020;31(Suppl 2):295-8
Management of Patients with Inflammatory Diseases during the COVID-19 Pandemic
Authors Information
1. President of the Hellenic Nephrological Society (HNS)
2. President of the Hellenic Study Group for Inflammatory Bowel Diseases (EOMIFNE)
2. Board Member of the Hellenic Study Group for Inflammatory Bowel Diseases (EOMIFNE)
3. President of the Hellenic Society for the Study of Liver (HASL)
4. President of the Hellenic Society of Dermatology and Venereology (HSDV)
5. President of the Hellenic Society of Gastroenterology (HSG)
6. President of the Greek Rheumatology Society & Professional Association of Rheumatologists (EPE-EPERE)
  1. Guidelines from the Greek National Organization of Public Health (EODY).Accessed at:https://eody.gov.gr/neos-koronaios-covid-19/
  2. Hellenic Dermatological and Venereological Society (HDVS): Recommendations in patients with Dermatological diseases under systematic treatment,. Accessed at: http://www.edae.gr/pdf/covid19_odigies.pdf
  3. The Greek Rheumatology Society and Professional Association of Rheumatologists (ERE-EPERE): Recommendations Regarding COVID19 Infection in Rheumatic Patients in Greece. Mediter J Rheumatol 2020;31;6-7.
  4. Recommendations of the Hellenic Study Group regarding the management of patients with IBD during the course of the COVID-19 pandemic (EOMIFNE). http://eomifne.gr/New/images/2020/COVID_19_2020_03_26.pdf
  5. ERA-EDTA: Information for nephrologists and other professionals on prevention and treatment of COVID-19 infections in kidney patients. Accessed at: https://www.era-edta.org/en/covid-19-news-and-information/   
  6. American Association for the Study of Liver Diseases (AASLD): Clinical insights for hepatology and liver transplant providers during the COVID-19 pandemic. Accessed at: https://www.aasld.org/sites/default/files/2020-04/AASLD-COVID19-ClinicalInsights-4.07.2020-Final.pdf  
  7. European Association for the Study of the Liver (EASL): Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. Accessed at: https://easl.eu/wp-content/uploads/2020/04/EASL-ESCMID-COVID-19-Position-Paper.pdf    
  8. American Academy of Dermatology: Guidance on the use of biologic agents during COVID-19 outbreak. Accessed at: https://assets.ctfassets.net/1ny4yoiyrqia/PicgNuD0IpYd9MSOwab47/07b614658aff5fc6ccc4c0bd910509a3/Biologics_and_COVID_19_FINAL_V2.pdf   
  9. American College of Rheumatology (ACR): COVID-19 Clinical Guidance for Patients with Rheumatic Diseases. https://www.rheumatology.org/Portals/0/Files/ACR-COVID-19-Clinical-Guidance-Summary-Patients-with-Rheumatic-Diseases.pdf   
  10. European League Against Rheumatism (EULAR): EULAR Guidance for patients COVID-19 outbreak. Accessed at: https://www.eular.org/eular_guidance_for_patients_covid19_outbreak.cfm   
  11. International Organization for the Study of Inflammatory Bowel Disease (IOIBD): Rubin DT, Abreu MT, Rai V, Siegel CA; International Organization for the Study of Inflammatory Bowel Disease. Management of Patients with Crohn's Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an International Meeting. Gastroenterology 2020;159:6-13.
  12. American Gastroenterology Association (AGA): Rubin DT, Feuerstein JD, Wang AY, Cohen RD, AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology. 2020;159:350-57.
  13. National Health System (NHS) -UK: Clinical guide for the management of rheumatology patients during the coronavirus pandemic (16 March 2020 Version 1). https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/clinical-guide-rheumatology-patients-v1-19-march-2020.pdf    
  14. National Institute for Health and Care Excellence (NICE) - UK: COVID-19 rapid guideline: rheumatological, autoimmune, inflammatory and metabolic bone disorders. Accessed at: https://www.nice.org.uk/guidance/NG167# (published April 3, 2020, updated July 2, 2020)   
  15. British Society for Rheumatologists (BSR): COVID-19: guidance for rheumatologists. Accessed at: https://www.rheumatology.org.uk/news-policy/details/covid19-coronavirus-update-members (updated July 29, 2020)
  16. Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD): Accessed at: https://covidibd.org/
  17. COVID-19 Global Rheumatology Alliance. Accessed at: https://rheum-covid.org/
  18. CDC: Groups at Higher Risk for Severe Illness. Accessed at:  https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html (revised July 17, 2020)   
  19. Public Health England: Guidance on shielding and protecting people defined on medical grounds as extremely vulnerable from COVID-19. Accessed at: https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19 (updated September 4, 2020)
  20. Massachusetts General Hospital (MGH): COVID-19 Treatment Guidance. Accessed at: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/mass-general-COVID-19-treatment-guidance.pdf (updated July 1, 2020)
  21. Massachusetts General Hospital (MGH): Risk Factors for COVID-19 Disease Progression. Accessed at: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/risk-factors-for-severe-COVID-19.pdf